Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell mobilisation
Authors:
- Seung Cheol ChoiSCSeung Cheol Choi
- Jae Sang KimJKJae Sang Kim
- Wan Joo ShimWSWan Joo Shim
- Seong Mi ParkSPSeong Mi Park
- Chul Min AhnCAChul Min Ahn
- Jae Hyung ParkJPJae Hyung Park
- Yong Hyun KimYKYong Hyun Kim
- Do-Sun LimDLDo-Sun Lim
Abstract
Objective To compare the effects of atorvastatin 10 mg versus 40 mg in circulating angiogenic cell mobilisations and in restoring coronary flow reserve (CFR) during the 8-month follow-up in patients with a first acute myocardial infarction (AMI). Design CFR was measured using an intracoronary Doppler wire in 102 patients with AMI at baseline and at 8 months. Changes in the absolute number of circulating angiogenic cells were measured at baseline, 1 day, 5 days and at 8 months. Stented patients were randomly assigned to either low-dose atorvastatin 10 mg (ATOR10, n=52) or moderate-dose atorvastatin 40 mg (ATOR40, n=50). Setting University Hospital. Results CFR increased significantly in both groups during the 8-month follow-up. The 8-month increases from baseline in CFR were significantly greater in the ATOR40 group than in the ATOR10 group (0.99±0.69 vs 0.55±0.47, p=0.017, respectively). The serial increases in the absolute number of CD34+ and CXCR4+ cells were significantly greater in the ATOR40 group, especially at 24 h after the procedure (two-way repeated-measures analysis of variance: p=0.046 and p=0.022, respectively). Decreases from baseline for interleukin 6 (−2.94±3.31 vs −1.52±2.82 pg/ml), tumour necrosis factor α (−1.31±2.96 vs −0.01±1.29 pg/ml), soluble intercellular adhesion molecule-1 (−71±95 vs 37±83 ng/ml) and soluble vascular cell adhesion molecule-1 (−51±364 vs 190±204 ng/ml) were significantly greater in the ATOR40 group. Conclusions The recovery of microvascular integrity after acute ischaemic injury in the ATOR40 group was expedited by greater circulating angiogenic cell mobilisations such as CD34+ and CXCR4+ cells, together with greater decreases in inflammatory cytokines and low-density lipoprotein-cholesterol concentrations. Registration number http://ClinicalTrials.gov number, NCT00536887.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic Implications of Coronary Flow Reserve on Left Anterior Descending Coronary Artery in Hypertrophic CardiomyopathyThe American Journal of Cardiology, 2008
- Models for Describing Relations Among the Various Statin Drugs, Low-Density Lipoprotein Cholesterol Lowering, Pleiotropic Effects, and Cardiovascular Risk††Conflicts of interest: In the past 2 years, Dr. Robinson has received grants from Abbott Laboratories, Abbott Park, Illinois, Astra-Zeneca, Wilmington, Delaware, Bristol-Myers Squibb, Princeton, New Jersey, GlaxoSmithKline, Pittsburgh, Pennsylvania, Hoffman La Roche, Basel, Switzerland, Merck & Company, West Point, Pennsylvania, Pfizer, New York, New York, Procter & Gamble, Cinncinnati, Ohio, Sankyo, Parsippany, New Jersey, Schering-Plough, Kenilworth, New Jersey, and Takeda Pharmaceuticals, Lincolnshire, Illinois and honoraria for education programs from Merck & Company, and has been a consultant and advisory board member for Merck Schering Plough.The American Journal of Cardiology, 2008
- Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive PatientsThe American Journal of Cardiology, 2007
- Secondary prevention for patients following a myocardial infarction: summary of NICE guidanceHeart, 2007
- Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapyClinical Therapeutics, 2007
- Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart FailureJACC, 2006
- Usefulness of coronary flow reserve immediately after primary coronary stenting in predicting wall motion recovery in patients with anterior wall acute myocardial infarctionThe American Journal of Cardiology, 2004
- Tackling the challenge of cardiovascular disease burden in developing countriesAmerican Heart Journal, 2004
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarctionThe American Journal of Cardiology, 1995